Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer‐BioNTech) in 112 Allo‐HSCT patients. Antibody response to SARS‐CoV‐2 spike protein receptor‐binding domain was tested at the time of the second injection (Roche Elecsys). The study also...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EJHaem
Hauptverfasser: Chevallier, Patrice, Coste‐Burel, Marianne, Le Bourgeois, Amandine, Peterlin, Pierre, Garnier, Alice, Béné, Marie C., Imbert, Berthe‐Marie, Drumel, Thomas, Le Gouill, Steven, Moreau, Philippe, Mahe, Beatrice, Dubruille, Viviane, Blin, Nicolas, Lok, Anne, Touzeau, Cyrille, Gastinne, Thomas, Jullien, Maxime, Vanthygem, Sophie, Guillaume, Thierry
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2021
Schlagworte:
Short Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8242867/
https://ncbi.nlm.nih.gov/pubmed/34226903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jha2.242
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge